info@cymabay.com
(510) 293-8800
Home
About
Overview
Management Team
Board of Directors
Careers
Clinical Trials
Pipeline
Overview
Seladelpar
Additional Programs
Expanded Access
Clinical Trials
Collaborations
News
Press Releases
Upcoming Events
Investors
Contact
Investors
Home
/
Investors
/
Press Releases
Press Releases
Overview
News / Events
Press Releases
Events
Presentations
Publications
Email Alerts
Company Information
Profile
Management Team
IR Contacts
FAQ
Financial Information
Financials
Quarterly Results
Stock Data
Quote
Charts
Historical Data
Analyst Coverage
SEC Filings
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Corporate Governance
Board of Directors
Board Committees
Governance Docs
Email Alerts
IR Contacts
RSS News Feed
All News
By Year:
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
3
Aug
CymaBay Announces Positive Topline Results from ENHANCE for Seladelpar in Patients with Primary Biliary Cholangitis
23
Jul
FDA Lifts All Clinical Holds on Seladelpar
19
Jun
CymaBay Therapeutics Presents Data at Digestive Disease Week 2020 Online Education
5
Jun
Notice of Change of Location of Annual Meeting of Stockholders to be Held on June 23, 2020
11
May
CymaBay Reports First Quarter 2020 Financial Results and Provides Corporate Update
4
May
CymaBay Therapeutics to Report First Quarter 2020 Financial Results on Monday, May 11
13
Mar
CymaBay Therapeutics Comments on Engine Capital Director Nominations
12
Mar
CymaBay Reports Fourth Quarter and Fiscal Year End 2019 Financial Results and Provides Corporate Update
5
Mar
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 12
29
Jan
CymaBay Publishes Shareholder Letter
<< Previous
1...
3
4
5
6
7
8
9
10
11
12
...26
Next >>
Show All
Scroll
